Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy

Nuklearmedizin. 2024 Jun;63(3):219-220. doi: 10.1055/a-2221-3220. Epub 2024 Jan 8.

Authors

Giulia Santo^{1

2}, Gianpaolo Di Santo¹, Bettina Zelger³, Irene Virgolini¹

Affiliations

¹ Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
² Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
³ Pathology, Medical University of Innsbruck, Innsbruck, Austria.

PMID: 38190993
DOI: 10.1055/a-2221-3220

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma* / diagnostic imaging
Adenocarcinoma* / radiotherapy
Aged
Dipeptides / therapeutic use
Edetic Acid / analogs & derivatives
Gallium Isotopes*
Gallium Radioisotopes*
Heterocyclic Compounds, 1-Ring / therapeutic use
Humans
Incidental Findings*
Lutetium* / therapeutic use
Male
Oligopeptides
Pancreatic Neoplasms* / diagnostic imaging
Pancreatic Neoplasms* / radiotherapy
Positron Emission Tomography Computed Tomography*
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / radiotherapy
Radiopharmaceuticals / therapeutic use

Substances

Gallium Radioisotopes
Gallium Isotopes
gallium 68 PSMA-11
Lutetium
Dipeptides
Heterocyclic Compounds, 1-Ring
Edetic Acid
Pluvicto
Radiopharmaceuticals
Oligopeptides
PSMA-11
Prostate-Specific Antigen